南美超级胎牛血清999尝鲜特惠
转染试剂低至5折
基质胶阶梯特惠
积分商城,好礼送不停
南美超级胎牛血清999尝鲜特惠
转染试剂低至5折
基质胶阶梯特惠
积分商城,好礼送不停
分子生物学
IVD分子诊断
细胞培养与分析
蛋白研究
细胞因子
重组蛋白
抗体
高通量测序建库
病原检测UCF系列
生物医药
工具酶
抑制剂激活剂与常用试剂
仪器
耗材

多组学整合分析揭示了919方剂在代谢功能障碍相关脂肪肝疾病中的治疗机制

Multi-omics integrated analysis reveals the therapeutic mechanism of 919 formula in metabolic dysfunction–associated steatotic liver disease

Yu Chen, Zihao Lin, Yue Niu, Qiaoqi Zheng, Manman Chen, Pengfei Gao

Journal:PHYTOMEDICINE

IF:11.3

DOI:10.1016/j.phymed.2026.158839

PMID:42854554

Published:2026-09-29

research field:分子生物学中医药药理学免疫学代谢性疾病系统生物学肝病学

Abstract

919 formula ameliorates hepatic steatosis and liver injury in HFD/MCD-induced MASLD models. • 919 formula is associated with reduced CD8⁺ T cell activation and cytotoxic function in experimental MASLD models. • Schizandrin C binds to PKM2 and is associated with suppressed glycolytic activity in CD8⁺ T cells. • Modulation of PKM2–STAT5 signaling may represent a potential immunometabolic strategy for MASLD treatment. Background Metabolic dysfunction–associated steatotic liver disease (MASLD) is the most prevalent chronic liver disease worldwide and is driven by metabolic stress–induced inflammation. Emerging evidence implicates cytotoxic CD8⁺ T cells as key contributors to the progression of MASLD. However, therapeutic strategies specifically targeting pathogenic CD8⁺ T cell responses in MASLD are still scarce. The clinical efficacy of the 919 formula in MASLD has been demonstrated, yet its cellular targets and molecular mechanisms remain unclear. Methods Single-cell transcriptomics profiled peripheral blood immune composition in 919 formula treated MASLD patients, and UPLC–QE-MS characterized bioactive constituents of the 919 formula. Efficacy and immune mechanisms were tested in HFD/MCD mouse models (AST/ALT and histology) and CD8⁺ T cell adoptive transfer. CD8⁺ T cells treated with control or 919 formula–containing serum were analyzed by flow cytometry, Seahorse assays, transcriptomics, immunoblotting, and molecular docking. Results Single-cell transcriptomic profiling showed that 919 formula treatment was associated with a selective reduction in circulating CD8⁺ GZMB⁺ T cells and an attenuation of CD8⁺ T-cell activation in patients with MASLD. In both HFD- and MCD-induced mouse models, the 919 formula markedly alleviated hepatic steatosis, inflammation, and fibrosis, which was accompanied by a decreased proportion of CD8⁺ GZMB⁺ T cells, reflecting reduced CD8⁺ T-cell activation. Furthermore, adoptive transfer experiments demonstrated that CD8⁺ T cells treated wi

本文使用的Yeasen产品

购物车
客服
转染试用